RT Journal Article
SR Electronic
T1 Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 976
OP 980
DO 10.3899/jrheum.181066
VO 46
IS 8
A1 Toby O. Smith
A1 Michael Mansfield
A1 Gillian A. Hawker
A1 David J. Hunter
A1 Lyn M. March
A1 Maarten Boers
A1 Beverley J. Shea
A1 Robin Christensen
A1 Francis Guillemin
A1 Caroline B. Terwee
A1 Paula R. Williamson
A1 Ewa M. Roos
A1 Richard F. Loeser
A1 Thomas J. Schnitzer
A1 Margreet Kloppenburg
A1 Tuhina Neogi
A1 Christoph H. Ladel
A1 Gurdyal Kalsi
A1 Ulrike Kaiser
A1 Thomas W. Buttel
A1 Anne E. Ashford
A1 Ali Mobasheri
A1 Nigel K. Arden
A1 Alan Tennant
A1 Marc C. Hochberg
A1 Maarten de Wit
A1 Peter Tugwell
A1 Philip G. Conaghan
YR 2019
UL http://www.jrheum.org/content/46/8/976.abstract
AB Objective. To assess the uptake of the OMERACT-OARSI (Outcome Measures in Rheumatology- Osteoarthritis Research Society International) core outcome set (COS) domains in hip and/or knee osteoarthritis (OA) trials.Methods. There were 382 trials of hip and/or knee OA identified from the ClinicalTrial.gov registry from 1997 to 2017. Frequency of COS adoption was assessed by year and per 5-yearly phases.Results. COS adoption decreased from 61% between 1997 and 2001 to 38% between 2012 and 2016. Pain (95%) and physical function (86%) were most consistently adopted. Patient’s global assessment (48%) was the principal missing domain.Conclusion. Limited adoption of the COS domains indicates that further consideration to improve uptake is required.